PFIZER TO TEST TWEAKED VACCINE TO TARGET SOUTH AFRICAN STRAIN

  • 25/02/2021

Pfizer and BioNTech have been studying adding a third dose to their vaccine regime and testing a new version that will target the South African variant of the coronavirus.

The South African variant is considered among the more dangerous of current mutations because it evades some of the blocking action of antibodies that target the older coronavirus strain. Concerns have since risen that more transmissible variants such as the one first detected in South Africa or another in Britain are more resistant to existing vaccines.That means people who were infected with the classic strain are more susceptible to reinfection, and research has also shown the variant has partly reduced the protection of the current generation of vaccines.

Related News